Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemiaMohamed L. Sorror, Elihu H. Estey, Barry E. Storer et al.|Blood|2021Cited by 46
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AMLMohamed L. Sorror, Elihu H. Estey, Ted Gooley et al.|Blood|2022Cited by 33
A Single Institution Respective Study of Tyrosine Kinase Inhibitor Cessation in Patients with Chronic Phase CML in MMRJames McCloskey, Stefan Faderl, Themba Nyirenda et al.|Blood|2015Cited by 3
Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United StatesAdam Albitar, Catherine Lai, Neil J. Shah et al.|Blood|2018Cited by 0
Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant RecurrenceJamie Koprivnikar, Andrew L. Pecora, James McCloskey et al.|Blood|2019Cited by 0